<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C0F9D147-D5D0-4833-B13A-53468BEB7501"><gtr:id>C0F9D147-D5D0-4833-B13A-53468BEB7501</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Mercer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3AEB4C1F-38DA-4B07-8871-1DEBDF07BD1C"><gtr:id>3AEB4C1F-38DA-4B07-8871-1DEBDF07BD1C</gtr:id><gtr:firstName>Rachel</gtr:firstName><gtr:otherNames>Clare</gtr:otherNames><gtr:surname>Chambers</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800265"><gtr:id>BF0059C7-BDF3-4B7A-AF58-40FB1C53AD37</gtr:id><gtr:title>Procoagulant signalling in acute lung injury.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800265</gtr:grantReference><gtr:abstractText>Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS) are devastating and often fatal clinical syndromes caused as a result of infection, trauma, exposure to lung toxicants and adverse drug reactions. The lungs respond to injury by becoming inflamed, accumulating fluid and activating a system of blood clotting proteins (coagulation factors) in order to temporarily plug damaged blood vessels. Aside from their roles in clotting, many of these coagulation factors can also directly influence inflammation. Under certain conditions their action can trigger an exaggerated inflammatory response, resulting in escalation of lung damage and in many cases, death of affected individuals. There are currently few effective therapies for ALI/ARDS, so that new treatments are urgently required. Our work with a new compound, has shown that a cell surface receptor, proteinase activated receptor-1 (PAR1), mediates the cellular effects of coagulation proteinases in an animal model of this condition and might offer promise as a novel therapeutic target. This project will begin to identify the potential of PAR1 antagonists in pre-clinical studies and will elucidate the mechanisms by which this receptor mediates lung inflammation and lung fluid accumulation, using an integrated experimental approach involving an experimental model of lung injury, cultured cells and patient biopsy and lung lavage samples. This information will help in the development of specific and effective therapies for these devastating conditions.</gtr:abstractText><gtr:technicalSummary>Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) represent common life-threatening conditions, resulting from a variety of local or systemic insults, including sepsis, pneumonia, trauma, and adverse drug reactions. Mortality remains high at 30-65% due to lack of effective therapies. ALI/ARDS is characterised by neutrophilic inflammation of the airspaces, widespread microvascular leak and activation of the extrinsic coagulation cascade in both intra- and extra-vascular compartments. Coagulation proteinases exert pluripotent cellular effects via activation of their signalling receptors, the proteinase activated receptors (PARs). Whilst there is good evidence that the major thrombin receptor, PAR1, induces cytokine release, adhesion molecule expression, endothelial barrier dysfunction and vascular permeability in certain disease settings, the role of PAR1 in ALI remains controversial. Our preliminary studies show that the potent and selective PAR1 antagonist (RWJ-58259) significantly reduces neutrophilia and microvascular-leak in a model of ALI based on direct alveolar insult with lipopolysaccharide (LPS). This was accompanied by a marked reduction in the expression of several PAR1-inducible chemokines which may represent novel mediators of neutrophil recruitment in this setting. This proposal will therefore address the following Hypothesis: Alveolar LPS insult results in the local activation of the extrinsic coagulation cascade leading to PAR1 dependent endothelial-epithelial barrier disruption and neutrophil recruitment. 
Aims: Our aims are to:
1. Determine the potential of PAR1 as a novel ?druggable? target in ALI using a potent and selective PAR1 antagonist.
2. Determine the relative contribution of the vascular compartment versus the alveolar compartment to PAR1-mediated signalling following direct alveolar insult with LPS by targeted expression of anticoagulants in transgenic mice.
3. Delineate the role of PAR1 induced chemokine networks in mediating neutrophil recruitment in this model of ALI by performing chemokine function blocking and reconstitution studies. 
4. Underscore the translational significance of these observations in mice to humans by analysis of lung lavage fluid of LPS challenged healthy volunteers and immunohistochemical studies of human ALI/ARDS lung tissue. 
Outcomes: Besides expanding our knowledge of the fundamental cross-talk between coagulation and inflammation in ALI, this research project will provide novel insights into the pathophysiological mechanisms underlying ALI and will explore the potential of PAR1 antagonists as novel and attractive agents for therapeutic intervention in ALI.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>395920</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Chemistry</gtr:department><gtr:description>UCL Chemistry</gtr:description><gtr:id>F2A30CCE-C92F-420E-8B43-876FC3CE785B</gtr:id><gtr:impact>Multi-disciplinary collaboration involving chemistry PhD students working in partnership with biomedical scientists with expertise in in vitro and in vivo models of lung injury, inflammation and repair. This collaboration resulted in 2 publications:
1. Synthesis of novel and potent vorapaxar analogues. Knight E, Robinson E, Smoktunowicz N, Chambers RC, Aliev AE, Inglis GG, Chudasama V, Caddick S. Org Biomol Chem. 2016 Mar 2. [Epub ahead of print] PMID: 26932831
2. Identification of an active metabolite of PAR-1 antagonist RWJ-58259 and synthesis of analogues to enhance its metabolic stability.
Robinson E, Knight E, Smoktunowicz N, Chambers RC, Inglis GG, Chudasama V, Caddick S. Org Biomol Chem. 2016 Mar 1. [Epub ahead of print] PMID: 26927018</gtr:impact><gtr:partnerContribution>Generation/modification of receptor antagonists for in vitro and in vivo evaluation in acute and chronic lung injury models</gtr:partnerContribution><gtr:piContribution>Assessment of novel receptor antagonists in models of acute and chronic lung injury</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MRC CASE Studentship with Novartis</gtr:description><gtr:id>B48A7AA6-F0F8-4400-B8DF-2F26F993FBEB</gtr:id><gtr:impact>A PhD thesis is due to be submitted by November 17th 2013.</gtr:impact><gtr:partnerContribution>Novartis are providing access to unique research material and platform technologies as part of this CASE studentship</gtr:partnerContribution><gtr:piContribution>Some of the data generated during this research agreement formed the basis of a successful proposal for an MRC-CASE studentship application with Novartis</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University of Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ALI/ARDS BALF</gtr:description><gtr:id>5C1355D8-216D-4F59-B5C1-B9DC5E72212C</gtr:id><gtr:impact>A manuscript describing the scientific findings made as a result of this collaboration is currently in preparation.</gtr:impact><gtr:partnerContribution>Our partners provided us with bronchoalveolar lavage fluid from patients with ALI/ARDS.</gtr:partnerContribution><gtr:piContribution>My research team demonstrated that a non-classical neutrophil chemokine contributed to the neutrophil chemotactic activity of bronchoalveolar lavage fluid obtained from patients with /ARDS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>190F7937-69F4-470C-B850-81A9A9581F3A</gtr:id><gtr:impact>My group hosts minimum of two GCSE or A level students per year for 1-2 weeks per student in order to for them to gain valuable experience of working in a medical research laboratory.

Many of the visiting students go on to study science to A level grade or went on to study science or medicine at university</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmaceutical Advisory Board Meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D09F8EEC-5A9F-479C-AA61-B8413F2CB3FC</gtr:id><gtr:impact>I have presented overviews of our research in the form of invited slide presentations and have participated in expert panel round-table discussions at Pharmaceutical Advisory Board Meetings.

This activity resulted in the submission of joint funding bids (CASE awards) and collaborative research funding with industry.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>254922</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical PhD Training Fellowship (Dr Arnab Datta: PAR-1 exerts pro-apoptotic and pro-fibrotic effects following lung injury via the induction of TNF-alpha)</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>084382</gtr:fundingRef><gtr:id>3D10C50E-F85F-4BC5-A794-88776A455CC1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1010560</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Career Development Fellowship (Crosstalk between extravascular coagulation, chemokine networks and immunity in fibroproliferative lung disease)</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0800340</gtr:fundingRef><gtr:id>54FAB48C-8380-4347-A4A6-6A67CE164DD8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London</gtr:department><gtr:description>UCL BRC</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:fundingRef>BRC76/HI/RC</gtr:fundingRef><gtr:id>4A9FF415-48FE-49A1-9BDA-2342F2147630</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCL Business (UCLB)</gtr:department><gtr:description>UCLB Proof of concept funding scheme</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>University College London (UCL)</gtr:fundingOrg><gtr:fundingRef>PoC-12-024</gtr:fundingRef><gtr:id>98D9CB66-B783-4FE6-8CA0-89A84B9BDAAE</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>272000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical PhD Training Fellowship (Dr R Jose: 23. Procoagulant signalling in Streptococcus pneumoniae induced acute lung injury)</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>097216/Z/11/Z</gtr:fundingRef><gtr:id>13409887-01D6-4E8F-8604-6F64A477A78F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE Studentship (Procoagulant signalling in lung injury and fibrosis)</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>896B5E09-5270-4BBF-B7EB-D4373865BE92</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Levels of CCL7 have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of CCL7 and/or other members of the PAR1-CCL7 axis,or CCL2can be used to prevent and/or treat these conditions.</gtr:description><gtr:id>2DC9A044-BFA4-43C6-81D0-981E6B1402AD</gtr:id><gtr:impact>Awarded UCL/BRC funding in order to prosecute the development of a novel intervention at the Stevenage Bioscience Catalyst.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013144563 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CCL7 in ALI</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Postgraduate Course Presentations at International Meetings</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>3ABD5ADC-4EA0-4846-BFA5-A811827D150F</gtr:id><gtr:impact>I have been invited to participate in a number of postgraduate courses at international conferences (organized by the European Respiratory Society -ERS and the American Thoracic Society- ATS) by presenting our research findings in the form of slide presentations.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E36807D-29BB-4334-9C5F-1D798D3E5348"><gtr:id>8E36807D-29BB-4334-9C5F-1D798D3E5348</gtr:id><gtr:title>The mercurial nature of neutrophils: still an enigma in ARDS?</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4caedb66bcfc1d4fcbe856af47164bdd"><gtr:id>4caedb66bcfc1d4fcbe856af47164bdd</gtr:id><gtr:otherNames>Williams AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA553D98-3739-44F6-8436-4B6A50A21963"><gtr:id>EA553D98-3739-44F6-8436-4B6A50A21963</gtr:id><gtr:title>Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fcb2b2ae2b48420e2e06b876baea5479"><gtr:id>fcb2b2ae2b48420e2e06b876baea5479</gtr:id><gtr:otherNames>Jos? RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85F23E1F-CBB4-4D66-9AD6-19BB77D254A8"><gtr:id>85F23E1F-CBB4-4D66-9AD6-19BB77D254A8</gtr:id><gtr:title>Coagulation cascade proteinases in lung injury and fibrosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81d8e8fced27cb1f73d84688e50dcbb6"><gtr:id>81d8e8fced27cb1f73d84688e50dcbb6</gtr:id><gtr:otherNames>Chambers RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1546-3222</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C3F3345-43A9-4A17-886B-16DF3E6FA86A"><gtr:id>3C3F3345-43A9-4A17-886B-16DF3E6FA86A</gtr:id><gtr:title>Mechanisms of alveolar epithelial injury, repair, and fibrosis.</gtr:title><gtr:parentPublicationTitle>Annals of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81d8e8fced27cb1f73d84688e50dcbb6"><gtr:id>81d8e8fced27cb1f73d84688e50dcbb6</gtr:id><gtr:otherNames>Chambers RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2325-6621</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66514E99-7976-42C7-916F-6B96F4AD2D86"><gtr:id>66514E99-7976-42C7-916F-6B96F4AD2D86</gtr:id><gtr:title>PAR-1-dependent and PAR-independent pro-inflammatory signaling in human lung fibroblasts exposed to thrombin.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c62516df7f907f9b98fab6227940c9c"><gtr:id>7c62516df7f907f9b98fab6227940c9c</gtr:id><gtr:otherNames>Ortiz-Stern A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F4241CF9-BFCC-40E6-9EB4-80E9EB3E2CAC"><gtr:id>F4241CF9-BFCC-40E6-9EB4-80E9EB3E2CAC</gtr:id><gtr:title>Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8b8cfc7ea3a76b19e21343fd04db9125"><gtr:id>8b8cfc7ea3a76b19e21343fd04db9125</gtr:id><gtr:otherNames>McGrath EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00CCCC8B-6604-45A4-BE39-6E6A21472ADB"><gtr:id>00CCCC8B-6604-45A4-BE39-6E6A21472ADB</gtr:id><gtr:title>Evidence for chemokine synergy during neutrophil migration in ARDS.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4caedb66bcfc1d4fcbe856af47164bdd"><gtr:id>4caedb66bcfc1d4fcbe856af47164bdd</gtr:id><gtr:otherNames>Williams AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9DA55B48-F730-47B2-B693-1F56D2436A59"><gtr:id>9DA55B48-F730-47B2-B693-1F56D2436A59</gtr:id><gtr:title>Enhanced inflammation in aged mice following infection with Streptococcus pneumoniae is associated with decreased IL-10 and augmented chemokine production.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4caedb66bcfc1d4fcbe856af47164bdd"><gtr:id>4caedb66bcfc1d4fcbe856af47164bdd</gtr:id><gtr:otherNames>Williams AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3BB8574-3409-41E3-9D2B-EEF7E7949F7B"><gtr:id>E3BB8574-3409-41E3-9D2B-EEF7E7949F7B</gtr:id><gtr:title>Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8264f3e245676159199c7659b0ef86cb"><gtr:id>8264f3e245676159199c7659b0ef86cb</gtr:id><gtr:otherNames>Mercer PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800265</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>